ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
20 Dezember 2023 - 1:30PM
ImmunoScape, a biotechnology company focused on the discovery and
development of next-generation T cell receptor (TCR)-based
therapeutics, and MiNK Therapeutics, Inc (Nasdaq: INKT), a clinical
stage biopharmaceutical company specializing in the discovery,
development and commercialization of allogeneic, off-the-shelf,
invariant natural killer T (iNKT) cell targeting therapies, today
announced a collaboration agreement to discover and develop
next-generation TCR therapies against novel targets in solid
tumors. The combined efforts of both companies aim to accelerate
the development of TCR-based therapies against novel targets in T
cells, iNKT cells, and other modalities, potentially offering new
therapeutic approaches for diverse cancer indications.
ImmunoScape’s unique Deep Immunomics platform enables
high-throughput and sensitive screening of T cells against relevant
tumor targets for the rapid discovery of rare,
therapeutically-relevant TCRs. MiNK Therapeutics has a proprietary
library of phospho-peptide neoantigens derived from a wide range of
solid tumors and hematologic malignancies. In this collaborative
effort, ImmunoScape will leverage its capabilities in multiplex
antigen screening and in-depth T cell profiling to identify
relevant TCRs targeting the library of phospho-peptide antigens.
MiNK Therapeutics will further characterize these tumor-specific
TCRs, leveraging its proprietary capabilities to analyze and select
TCR candidates for optimal tumor targeting.
“ImmunoScape’s mission is to utilize our Deep Immunomics
platform to enable the expedited discovery of novel, safe, and
efficacious TCRs,” said Choon Peng Ng, Chief Executive Officer,
ImmunoScape. “Natural TCRs identified with ImmunoScape’s platform
can be deployed via multiple therapeutic modalities, including T
cell and via MiNK Therapeutics in iNKT cell therapies and
bispecific immune cell engagers. We are excited to work closely
with the team at MiNK Therapeutics to fast track the development of
next generation TCR-based therapies for solid tumors.”
“We have leveraged our proprietary iNKT discovery platform to
develop a wholly owned library of both native and engineered
allogeneic cell therapies, including bispecific iNKT cell engagers
and TCRs targeting a range of antigens, such as PRAME, NY-ESO-1,
and undisclosed targets,” said Dr. Jennifer Buell, President and
Chief Executive Officer, MiNK Therapeutics. “We look forward to
working with the ImmunoScape team to help fill a crucial gap in
delivering TCR-iNKT cells and bispecific immune cell engagers.
These therapeutics, armored with tumor-specific TCRs, can
potentially eliminate tumor cells and alleviate immune suppression
for durable anti-cancer immunity.”
To learn more about ImmunoScape, please visit
https://immunoscape.com/.
To learn more about MiNK Therapeutics, please visit
https://minktherapeutics.com/.
About ImmunoScape ImmunoScape is a pre-clinical
biotechnology company focused on the discovery and development of
next-generation TCR cell therapies in the field of oncology. The
company's proprietary Deep Immunomics technology and machine
learning platforms enable highly sensitive, large-scale mining and
immune profiling of T cells in cancer patient samples to identify
novel, therapeutically relevant TCRs across multiple types of solid
tumors. ImmunoScape has multiple discovery programs ongoing and is
progressing towards IND-enabling studies and entry into the clinic.
For more information, please
visit https://immunoscape.com/.
About MiNK TherapeuticsMiNK
Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery, development and commercialization of
allogeneic invariant natural killer T (iNKT) cell therapies to
treat cancer and other immune-mediated diseases. MiNK is advancing
a pipeline of both native and next generation engineered iNKT
programs, with a platform designed to facilitate scalable and
reproducible manufacturing for off-the-shelf delivery. The company
is headquartered in New York, New York. For more information,
visit https://minktherapeutics.com/ or @MiNK_iNKT. Information
that may be important to investors will be routinely posted on our
website and social media channels.
Forward Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding the therapeutic potential, anticipated
benefit, plans and timelines of iNKT cells and TCRs, as well as the
collaboration between MiNK and ImmunoScape. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These forward-looking
statements are subject to risks and uncertainties, including the
factors described under the Risk Factors section of the most recent
Form 10-K, Form 10-Q and the S-1 Registration Statement filed with
the SEC. MiNK cautions investors not to place considerable reliance
on the forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
MiNK undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
For Immunoscape:Media ContactKalyn
Kolekkos@anzupartners.com
For MiNK: Investor
Contact917-362-1370investor@minktherapeutics.com
Media Contact781-674-4428communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
MiNK Therapeutics (NASDAQ:INKT)
Historical Stock Chart
Von Jan 2024 bis Jan 2025